Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Epilepsy in various metabolic disorders

여러 가지 대사질환에서의 간질

  • Lee, Young-Mock (Department of Pediatrics, Yonsei University College of Medicine)
  • 이영목 (연세대학교 의과대학 소아과학교실)
  • Received : 2008.11.12
  • Accepted : 2008.11.14
  • Published : 2008.12.15
Download PDF
⟨ Previous Next ⟩

Abstract

Seizures are a frequent symptom in metabolic disorders, although metabolic disorders are rarely found to be the cause of epilepsy. A precise diagnosis might not only influence treatment, but it might also call for counseling of the family, even if there are no direct therapeutic consequences. We review the main characteristics of epilepsy in metabolic disorders with regard to energy metabolism, toxic effects, neurotransmitters, and vitamins.

Keywords

References

  1. Anne T. Berg. Epidemiologic Aspects of Epilepsy. In: Wyllie E. The treatment of epilepsy. 4th edition. Philadelphia: Lippincott Williams & Wilkins, 2006:109-16
  2. Pearl PL, Bennett HD, Khademian Z. Seizures and metabolic disease. Curr Neurol Neurosci 2005;5:127-33 https://doi.org/10.1007/s11910-005-0010-7
  3. Wolf NI, Bast T, Surtees R. Epilepsy in inborn errors of metabolism. Epileptic Disord 2005;7:67-81
  4. Darin N, Oldfors A, Moslemi AR, Holme E, Tulinius M. The incidence of mitochondrial encephalomyopathies in childhood: clinical features and morphological, biochemical, and DNA anbormalities. Ann Neurol 2001;49:377-83 https://doi.org/10.1002/ana.75
  5. Lee YM, Kang HC, Lee JS, Kim SH, Kim EY, Lee SK, et al. Mitochondrial respiratory chain defects: underlying etiology in various epileptic conditions. Epilepsia 2008;49:685-90 https://doi.org/10.1111/j.1528-1167.2007.01522.x
  6. Kunz WS. The role of mitochondria in epileptogenesis. Curr Opin Neurol 2002;15:179-84 https://doi.org/10.1097/00019052-200204000-00009
  7. So N, Berkovic S, Andermann F, Kuzniecky R, Gendron D, Quesney LF. Myoclonus epilepsy and ragged-red fibres (MERRF). 2. Electrophysiological studies and comparison with other progressive myoclonus epilepsies. Brain 1989;112: 1261-76 https://doi.org/10.1093/brain/112.5.1261
  8. Sadleir LG, Connolly MB, Applegarth D, Hendson G, Clarke L, Rakshi C, et al. Spasms in children with definite and probable mitochondrial disease. Eur J Neurol 2004;11:103-10 https://doi.org/10.1046/j.1351-5101.2003.00724.x
  9. Kang HC, Lee YM, Kim HD, Lee JS, Slama A. Safe and effective use of the ketogenic diet in children with epilepsy and mitochondrial respiratory chain complex defects. Epilepsia 2007;48:82-8
  10. Salomons GS, van Dooren SJ, Verhoeven NM, Cecil KM, Ball WS, Degrauw TJ, et al. X-linked creatine-transporter gene (SLC6A8) defect: a new creatinedeficiency syndrome. Am J Hum Genet 2001;68:1497-500 https://doi.org/10.1086/320595
  11. Stockler S, Isbrandt D, Hanefeld F, Schmidt B, von Figura K. Guanidinoacetate methyltransferase deficiency: the first inborn error of creatine metabolism in man. Am J Hum Genet 1996;58:914-22
  12. Schulze A, Bachert P, Schlemmer H, Harting I, Polster T, Salomons GS, et al. Lack of creatine in muscle and brain in an adult with GAMT deficiency. Ann Neurol 2003;53:248-51 https://doi.org/10.1002/ana.10455
  13. Schulze A, Ebinger F, Rating D, Mayatepek E. Improving treatment of guanidinoacetate methyltransferase deficiency: reduction of guanidinoacetic acid in body fluids by arginine restriction and ornithine supplementation. Mol Genet Metab 2001;74:413-9 https://doi.org/10.1006/mgme.2001.3257
  14. Seidner G, Alvarez MG, Yeh JI, O'Driscoll KR, Klepper J, Stump TS, et al. GLUT-1 deficiency syndrome caused by haploinsufficiency of the blood-brain barrier hexose carrier. Nat Genet 1998;18:188-91 https://doi.org/10.1038/ng0298-188
  15. Brockmann K, Wang D, Korenke CG, von Moers A, Ho YY, Pascual JM, et al. Autosomal dominant glut-1 deficiency syndrome and familial epilepsy. Ann Neurol 2001;50:476-85 https://doi.org/10.1002/ana.1222
  16. Wang D, Pascual JM, Yang H, Engelstad K, Jhung S, Sun RP, et al. Glut-1 deficiency syndrome: clinical, genetic, and therapeutic aspects. Ann Neurol 2005;57:111-8 https://doi.org/10.1002/ana.20331
  17. Klepper J, Fischbarg J, Vera JC, Wang D, De Vivo DC. GLUT1-deficiency: barbiturates potentiate haploinsufficiency in vitro. Pediatr Res 1999;46:677-83 https://doi.org/10.1203/00006450-199912000-00007
  18. Yanling Y, Qiang G, Zhixiang Z, Chunlan M, Lide W, Xiru W. A clinical investigation of 228 patients with phenylketonuria in mainland China. Southeast Asian J Trop Med Public Health 1999;30(2 Suppl):58S-60S
  19. Zschocke J, Ruiter JP, Brand J, Lindner M, Hoffmann GF, Wanders RJ, et al. Progressive infantile neurodegeneration caused by 2-methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency: a novel inborn error of branched-chain fatty acid and isoleucine metabolism. Pediatr Res 2000;48:852-5 https://doi.org/10.1203/00006450-200012000-00025
  20. Castro M, Prez-CerdC, Merinero B, Garca MJ, Bernar J, Gil Nagel A, et al. Screening for adenylosuccinate lyase deficiency: clinical, biochemical and molecular findings in four patients. Neuropediatrics 2002;33:186-9 https://doi.org/10.1055/s-2002-34493
  21. Van Kuilenburg AB, Vreken P, Abeling NG, Bakker HD, Meinsma R, Van Lenthe H, et al. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet 1999;104:1-9 https://doi.org/10.1007/PL00008711
  22. Applegarth DA, Toone JR. Glycine encephalopathy (nonketotic hyperglycinaemia): review and update. J Inherit Metab Dis 2004;27:417-22 https://doi.org/10.1023/B:BOLI.0000031222.38328.59
  23. Thomson AM. Glycine is a coagonist at the NMDA receptor/ channel complex. Prog Neurobiol 1990;35:53-74 https://doi.org/10.1016/0301-0082(90)90040-N
  24. Hamosh A, Maher JF, Bellus GA, Rasmussen SA, Johnston MV. Long-term use of high-dose benzoate and dextromethorphan for the treatment of nonketotic hyperglycinemia. J Pediatr 1998;132:709-13 https://doi.org/10.1016/S0022-3476(98)70365-8
  25. Jaeken J. Genetic disorders of gamma-aminobutyric acid, glycine, and serine as causes of epilepsy. J Child Neurol 2002;17(3 Suppl):84S-87S
  26. Pearl PL, Gibson KM, Acosta MT, Vezina LG, Theodore WH, Rogawski MA, et al. Clinical spectrum of succinic semialdehyde dehydrogenase deficiency. Neurology 2003;60: 1413-7 https://doi.org/10.1212/01.WNL.0000059549.70717.80
  27. Gropman A. Vigabatrin and newer interventions in succinic semialdehyde dehydrogenase deficiency. Ann Neurol 2003;54 (6 Suppl):66S-72S https://doi.org/10.1002/ana.10592
  28. Cormier-Daire V, Dagoneau N, Nabbout R, Burglen L, Penet C, Soufflet C, et al. A gene for pyridoxine-dependent epilepsy maps to chromosome 5q31. Am J Hum Genet 2000;67: 991-3 https://doi.org/10.1086/303087
  29. Baxter P, Griffiths P, Kelly T, Gardner-Medwin D. Pyridoxinedependent seizures: demographic, clinical, MRI and psychometric features, and effect of dose on intelligence quotient. Dev Med Child Neurol 1996;38:998-1006 https://doi.org/10.1111/j.1469-8749.1996.tb15060.x
  30. Clayton PT, Surtees RA, DeVile C, Hyland K, Heales SJ. Neonatal epileptic encephalopathy. Lancet 2003;361:1614 https://doi.org/10.1016/S0140-6736(03)13312-0
  31. Torres OA, Miller VS, Buist NM, Hyland K. Folinic acidresponsive neonatal seizures. J Child Neurol 1999;14:529-32 https://doi.org/10.1177/088307389901400809
  32. Collins JE, Nicholson NS, Dalton N, Leonard JV. Biotinidase deficiency: early neurological presentation. Dev Med Child Neurol 1994;36:268-70 https://doi.org/10.1111/j.1469-8749.1994.tb11840.x
  33. Salbert BA, Pellock JM, Wolf B. Characterization of seizures associated with biotinidase deficiency. Neurology 1993;43: 1351-5 https://doi.org/10.1212/WNL.43.7.1351